Huaxia Eye Hospital GroupLtd Future Growth
Future criteria checks 4/6
Huaxia Eye Hospital GroupLtd is forecast to grow earnings and revenue by 25.5% and 13.5% per annum respectively. EPS is expected to grow by 25.6% per annum. Return on equity is forecast to be 10.5% in 3 years.
Key information
25.5%
Earnings growth rate
25.63%
EPS growth rate
| Healthcare earnings growth | 20.6% |
| Revenue growth rate | 13.5% |
| Future return on equity | 10.47% |
| Analyst coverage | Low |
| Last updated | 14 May 2025 |
Recent future growth updates
Recent updates
Huaxia Eye Hospital GroupLtd (SZSE:301267) May Have Issues Allocating Its Capital
Mar 05
Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Screens Well But There Might Be A Catch
Feb 06Is Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Expensive For A Reason? A Look At Its Intrinsic Value
Dec 23Here's What's Concerning About Huaxia Eye Hospital GroupLtd's (SZSE:301267) Returns On Capital
Oct 28Huaxia Eye Hospital Group Co.,Ltd.'s (SZSE:301267) 43% Price Boost Is Out Of Tune With Earnings
Sep 30Huaxia Eye Hospital GroupLtd's (SZSE:301267) Conservative Accounting Might Explain Soft Earnings
Sep 04Does Huaxia Eye Hospital GroupLtd (SZSE:301267) Have A Healthy Balance Sheet?
Aug 19Huaxia Eye Hospital GroupLtd's (SZSE:301267) Dividend Is Being Reduced To CN¥0.11
Jul 12Huaxia Eye Hospital GroupLtd (SZSE:301267) Has Some Way To Go To Become A Multi-Bagger
Jun 06Analysts Just Shaved Their Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Forecasts Dramatically
May 01Huaxia Eye Hospital GroupLtd (SZSE:301267) Seems To Use Debt Rather Sparingly
Feb 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 5,524 | 638 | N/A | 971 | 1 |
| 12/31/2026 | 5,515 | 799 | N/A | 1,083 | 4 |
| 12/31/2025 | 4,428 | 507 | N/A | 769 | 2 |
| 3/31/2025 | 4,142 | 422 | 612 | 868 | N/A |
| 12/31/2024 | 4,027 | 429 | 541 | 820 | N/A |
| 9/30/2024 | 4,092 | 529 | 507 | 910 | N/A |
| 6/30/2024 | 4,070 | 577 | 515 | 955 | N/A |
| 3/31/2024 | 4,061 | 672 | 405 | 867 | N/A |
| 12/31/2023 | 4,013 | 666 | 513 | 961 | N/A |
| 9/30/2023 | 3,813 | 674 | 517 | 880 | N/A |
| 6/30/2023 | 3,648 | 632 | 510 | 798 | N/A |
| 3/31/2023 | 3,355 | 552 | 656 | 872 | N/A |
| 1/1/2023 | 3,233 | 514 | 535 | 770 | N/A |
| 9/30/2022 | 3,297 | 516 | 688 | 871 | N/A |
| 1/1/2022 | 3,064 | 455 | 624 | 798 | N/A |
| 9/30/2021 | 2,998 | 445 | 552 | 731 | N/A |
| 12/31/2020 | 2,515 | 334 | 427 | 591 | N/A |
| 12/31/2019 | 2,456 | 218 | 188 | 444 | N/A |
| 12/31/2018 | 2,146 | 164 | N/A | 291 | N/A |
| 12/31/2017 | 1,543 | 78 | N/A | 298 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301267's forecast earnings growth (25.5% per year) is above the savings rate (2.7%).
Earnings vs Market: 301267's earnings (25.5% per year) are forecast to grow faster than the CN market (23.5% per year).
High Growth Earnings: 301267's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301267's revenue (13.5% per year) is forecast to grow faster than the CN market (12.4% per year).
High Growth Revenue: 301267's revenue (13.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301267's Return on Equity is forecast to be low in 3 years time (10.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 06:10 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huaxia Eye Hospital Group Co.,Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | China International Capital Corporation Limited |
| Yichi Zhang | China International Capital Corporation Limited |
| Shuo Song | Citic Securities Co., Ltd. |